Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Glox001
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Recipient : Glox Therapeutics
Deal Size : $0.6 million
Deal Type : Funding
Glox Therapeutics Awarded £3M for Cystic Fibrosis Antimicrobial Resistance Study
Details : The funding will be used to accelerate the development of novel precision antibiotics, including Glox001, to overcome antimicrobial-resistant lung infections with cystic fibrosis.
Product Name : Undisclosed
Product Type : Antibiotic
Upfront Cash : Undisclosed
January 21, 2025
Lead Product(s) : Glox001
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Recipient : Glox Therapeutics
Deal Size : $0.6 million
Deal Type : Funding
Lead Product(s) : Undisclosed
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Discovery
Recipient : H3D Foundation
Deal Size : $7.2 million
Deal Type : Series A Financing
LifeArc Makes Investment to Support Drug Discovery in Sub-Saharan Africa
Details : This funding will bolster five drug discovery initiatives in Africa, spanning 3-5 years. H3D Foundation's primary focus lies in addressing life-threatening diseases like malaria and tuberculosis.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
January 31, 2024
Lead Product(s) : Undisclosed
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Discovery
Recipient : H3D Foundation
Deal Size : $7.2 million
Deal Type : Series A Financing
Lead Product(s) : Undisclosed
Therapeutic Area : Neurology
Study Phase : Preclinical
Recipient : Undisclosed
Deal Size : $6.2 million
Deal Type : Funding
LifeArc Announces £5 million Drug Repurposing Programme for Motor Neuron Disease
Details : The net proceeds will be used to find new treatments for motor neuron disease (MND) as part of a drug repurposing programme to tackle the high failure rate in MND clinical trials.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
June 12, 2023
Lead Product(s) : Undisclosed
Therapeutic Area : Neurology
Highest Development Status : Preclinical
Recipient : Undisclosed
Deal Size : $6.2 million
Deal Type : Funding
Lead Product(s) : Undisclosed
Therapeutic Area : Neurology
Study Phase : Discovery
Recipient : Metrion Biosciences
Deal Size : Undisclosed
Deal Type : Collaboration
Details : The collaboration focuses on the discovery of novel selective small molecular modulators of a specific two-pore potassium ion target, identified as likely to be involved in neurological pathogenesis, and has now progressed to the hit-to-lead optimization...
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
January 18, 2021
Lead Product(s) : Undisclosed
Therapeutic Area : Neurology
Highest Development Status : Discovery
Recipient : Metrion Biosciences
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Favipiravir
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Recipient : University College, London
Deal Size : Inapplicable
Deal Type : Inapplicable
FLARE: Favipiravir +/- Lopinavir: A RCT of Early Antivirals
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 05, 2020
Lead Product(s) : Favipiravir
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Recipient : University College, London
Deal Size : Inapplicable
Deal Type : Inapplicable